Local investment
August 2, 2011
ONEVENTURES, Brandon Capital,
the Medical Healthcare Diagnostics
and Research Commercialisation
Fund (MRCF), and US-based
HealthCare Ventures have coinvested
in a start-up biotechnology
company, Vaxxas Pty Ltd.
Descrtibed as one of Australia’s
largest ever investments into a new
biotech company, the AU$15m
Vaxxas was formed with the aim of
of developing a revolutionary new
needle-free vaccine delivery
system, Nanopatch.
Spearheading the reseacrch and
development of Nanopatch is
Professor Mark Kendall of the
University of Queensland’s
Australian Institute for
Bioengineering and
Nanotechnology.
The Nanopatch works via
thousands of small projections
designed to deliver the vaccine to
abundant immune cells in the skin,
and if successful would eliminate
the need for the cold chain (vaccine
refrigeration).
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Aug 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Aug 11
